EUVIMEDEUVIMED entdecken
Vergleichsstudie

Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma

Yong-Kui Yu, Fan-Yu Meng, Xiu-Feng Wei, Xian-Kai Chen, Hao-Miao Li, Qi Liu, Can-Jun Li, Hou-Nai Xie, Lei Xu, Rui-Xiang Zhang, Wenqun Xing, Yin Li

The Journal of Thoracic and Cardiovascular Surgery · 2024-08 · 168 (2) · 417-428.e3

DOI: 10.1016/j.jtcvs.2023.12.030 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2024-08. Verfasst von Yong-Kui Yu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/C…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: To date, few studies have compared effectiveness and survival rates of neoadjuvant chemotherapy combined with immunotherapy (NACI) and conventional neoadjuvant chemoradiotherapy (NCRT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). The present study was conducted to compare therapeutic response and survival between NACI and NCRT. METHODS: The study cohort comprised patients with locally advanced ESCC treated with either NACI or NCRT followed by surgery between June 2018 and March 2021. The 2 groups were compared for treatment response, 3-year overall survival (OS), and disease-free survival (DFS). Survival curves were created using the Kaplan-Meier method, differences were compared using the log-rank test, and potential imbalances were corrected for using the inverse probability of treatment weighting (IPTW) method. RESULTS: Among 202 patients with locally advanced ESCC, 81 received NACI and 121 received conventional NCRT. After IPTW adjustment, the R0 resection rate (85.2% vs 92.3%; P = .227) and the pathologic complete response (pCR) rate (27.5% vs 36.4%; P = .239) were comparable between the 2 groups. Nevertheless, patients who received NACI exhibited both a better 3-year OS rate (91.7% vs 79.8%; P = .032) and a better 3-year DFS rate (87.4% vs 72.8%; P = .039) compared with NCRT recipients. CONCLUSIONS: NACI has R0 resection and pCR rates comparable to those of NCRT and seems to be correlated with better prognosis than NCRT. NACI followed by surgery may be an effective treatment strategy for locally advanced ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsNeoadjuvant TherapyHumansMaleFemaleMiddle AgedAgedRetrospective StudiesEsophagectomyImmunotherapyChemoradiotherapy, AdjuvantChemotherapy, AdjuvantTreatment OutcomeDisease-Free SurvivalChemoradiotherapy

Stichwörter der Autor:innen

esophageal squamous cell carcinomaneoadjuvant chemoradiotherapyneoadjuvant immunotherapysurvivaltreatment response

Autor:innen und Institutionen

  • Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union M…
  • Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin Province, China.
  • The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan Province, China.
  • Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
  • Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan Province, China. Electronic address: xingwenqun@sina.com.

Förderung

  • Ministry of Science and Technology of the People's Republic of China

Zitieren

APA

Yu, Y. K., Meng, F. Y., Wei, X. F., Chen, X. K., Li, H. M., Liu, Q., Li, C. J., Xie, H. N., Xu, L., Zhang, R. X., Xing, W., & Li, Y. (2024). Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. The Journal of Thoracic and Cardiovascular Surgery, 168(2), 417-428.e3. https://doi.org/10.1016/j.jtcvs.2023.12.030

Vancouver

Yu YK, Meng FY, Wei XF, Chen XK, Li HM, Liu Q, et al. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. The Journal of Thoracic and Cardiovascular Surgery. 2024;168(2):417-428.e3. doi:10.1016/j.jtcvs.2023.12.030

BibTeX
@article{Yu2024,
  author = {Yu, Yong-Kui and Meng, Fan-Yu and Wei, Xiu-Feng and Chen, Xian-Kai and Li, Hao-Miao and Liu, Qi and Li, Can-Jun and Xie, Hou-Nai and Xu, Lei and Zhang, Rui-Xiang and Xing, Wenqun and Li, Yin},
  title = {Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2024},
  volume = {168},
  number = {2},
  pages = {417--428.e3},
  doi = {10.1016/j.jtcvs.2023.12.030}
}
Kostenlos starten →